CTLA4 and type 1 diabetes mellitus: An increased risk for developing T1DM was associated with combination therapy of anti-PD-1 and anti-CTLA-4 (compared with anti-PD-1 monotherapy, OR, 3.78; 95% CI, 1.87-7.65; P < .01) (Fig. 2).